Figure 1.
Comparison of OS markers in patients with CAP and CHF_
| Parameters | Group 1 (n = 105) | Group 2 (n = 105) | F | P | ||
|---|---|---|---|---|---|---|
| Mean | SD± | Mean | SD± | |||
| AIM (μM/L) | 229.7775 | 57.23919 | 236.6077 | 64.35578 | 0.660 | 0.417 |
| AGE-pentosidine-like (μM/L) | 598.7908 | 251.68051 | 544.5575 | 197.20439 | 3.021 | 0.084 |
| AGE-verperlisin-like (μM/L) | 449.1497 | 169.38287 | 455.2475 | 160.66932 | 0.072 | 0.789 |
| PPOA (μM/L) | 95.2128 | 63.05108 | 105.9567 | 55.21101 | 1.726 | 0.190 |
| Catalase (μM/L) | 21.8819 | 10.01078 | 23.1646 | 11.54527 | 0.740 | 0.391 |
| AAT with CUPRAC (μM/L) | 6.7012 | 4.62461 | 4.9987 | 4.29101 | 7.647 | 0.006 |
| AAT with ABTS (μM/L) | 132.2233 | 21.48573 | 128.2355 | 22.21592 | 1.748 | 0.188 |
| SOD (u/c) | 62.7206 | 13.37431 | 62.3362 | 16.47029 | 0.034 | 0.853 |
| MDA (μM/L) | 17.4629 | 6.94660 | 16.0739 | 4.72922 | 2.869 | 0.092 |
Concomitant diseases in patients with CAP and CHF_
| Group 1 (n = 105) | Group 2 (n = 105) | P, df = 1 | |||
|---|---|---|---|---|---|
| Abs. | % | Abs. | % | ||
| Dyslipidaemia | 20 | 19.0 | 16 | 15.2 | χ2 = 0.536; P = 0.464 |
| Chronic liver disease | 13 | 12.4 | 8 | 7.6 | χ2 = 1.323; P = 0.250 |
| Atrial fibrillation | 54 | 51.4 | 0 | 0 | χ2 = 72.692; P < 0.0001 |
| Arterial hypertension | 103 | 98.0 | 84 | 80.1 | χ2 = 19.552; P < 0.0001 |
| Chronic kidney disease | 21 | 20.0 | 6 | 5.7 | χ2 = 9.563; P = 0.002 |
| Type 2 diabetes mellitus | 41 | 39.0 | 25 | 23.8 | χ2 = 5.657; P = 0.017 |
| Cerebrovascular disease | 47 | 44.8 | 25 | 23.8 | χ2 = 10.229; P = 0.001 |